A Kinase EGFR that acts on EGFR-sensitive mutants l858r ,egfr (d746‑750) 6-substituted aminopurine compounds and applications thereof
A technology of aminopurine and compound, which is applied in the field of medicinal chemistry, can solve the problems of large side effects and low effect of EGFR inhibitors, and achieve high-efficiency treatment of tumors
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0024] The synthesis of embodiment 1 compound 6-(5-chloro-pyrrole-2-methylamino)purine (A1)
[0025] 1 Synthetic route of the compound
[0026] The specific synthetic route is as figure 1 shown.
[0027] 2 synthetic steps
[0028] 2.1 Preparation of 6-(5-chloro-pyrrole-2-methylamino)purine (A1)
[0029] Measure 5ml of n-butanol, weigh 80mg of 6-chloropurine and 100mg of (5-chloro-1H-pyrrol-2-yl)methylamine, put them into a 25ml round bottom flask, and add 50μl of triethyl Amines act as catalysts and are added to a stir bar. Heated to reflux in an oil bath at 110°C for 5h, cooled, until a white solid precipitated out, filtered under reduced pressure, washed twice with n-butanol, and dried to obtain 6-(5-chloro-pyrrole-2-methylamino)purine (A1 ).
[0030] 2.2 Physical characteristics of 6-(5-chloro-pyrrole-2-methylamino)purine (A1)
[0031] 1 H-NMR (DMSO-d 6 )δ(ppm): 12.987(s,1H,7'or 9'-Purine-H), 8.220(s,1H,-NH), 8.140-8.15(m, 2H,2',8'-Purine-H ), 7.858(s,1H,1'-Pyrrol...
Embodiment 2
[0032] The synthesis of embodiment 2 compound 6-(6-chloro-pyrimidine-4-methylamino)purine (A2)
[0033] 1 Synthetic route of the compound
[0034] The specific synthetic route is as figure 2 shown.
[0035] 2 synthetic steps
[0036] 2.1 Preparation of 6-(6-chloro-pyrimidine-4-methylamino)purine (A2)
[0037] Measure 5ml of n-butanol, weigh 80mg of 6-chloropurine and 120mg of (6-chloropyrimidin-4-yl)methylamine, put them into a 25ml round bottom flask, and add 50μl of triethylamine as a catalyst , add a stir bar. Heated to reflux in an oil bath at 110°C for 5h, cooled until a white solid precipitated, filtered under reduced pressure, washed twice with n-butanol, and dried to obtain 6-(6-chloro-pyrimidine-4-methylamino)purine (A2 ).
[0038] 2.2 Physical characteristics of 6-(6-chloro-pyrimidine-4-methylamino)purine (A2)
[0039] 1 H-NMR (DMSO-d 6 )δ(ppm): 13.276(s,1H,7'or 9'-Purine-H), 9.432(s,1H,2'-Pyrimidine-H), 8.720(s,1H,-NH-), 8.125- 8.243(m,2H,2',8'-Purine-H),...
Embodiment 3
[0040] Example 3 compound in vitro EGFR inhibitory activity test
[0041] Screening of EGFR kinase activity in vitro: The method used in the experiment is Caliper Mobility Shift Assay, which is a detection platform based on the mobility detection technology of microfluidic chip technology. The specific experimental steps are: configure 1.25x kinase reaction buffer (62.5mmol / L HEPES, pH7.5; 0.001875% Brij-35; 12.5mmol / LMgCl 2; 2.5mmol / L DTT) and kinase reaction stop solution (100mmol / L HEPES, pH7.5; 0.015% Brij-35; 0.2% Coating Reagent#3); in 5μl of 5x concentration compound solution (DMSO dissolved, diluted with water 10 times) add 10 μl of 2.5x EGFR kinase solution (add kinase in 1.25x kinase reaction buffer), react at room temperature for 10 minutes, then add 10 μl of 2.5x substrate peptide solution (add FAM in 1.25x kinase reaction buffer labeled peptide and ATP), after reacting at 28°C for a specific time, 25 μl of kinase reaction stop solution was added. Collect data on...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


